Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2015 1
2018 1
2019 1
2020 1
2022 1
2023 3

Text availability

Article attribute

Article type

Publication date

Search Results

6 results

Results by year

Filters applied: . Clear all
Page 1
89Zr-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer.
Bensch F, van der Veen EL, Lub-de Hooge MN, Jorritsma-Smit A, Boellaard R, Kok IC, Oosting SF, Schröder CP, Hiltermann TJN, van der Wekken AJ, Groen HJM, Kwee TC, Elias SG, Gietema JA, Bohorquez SS, de Crespigny A, Williams SP, Mancao C, Brouwers AH, Fine BM, de Vries EGE. Bensch F, et al. Among authors: bohorquez ss. Nat Med. 2018 Dec;24(12):1852-1858. doi: 10.1038/s41591-018-0255-8. Epub 2018 Nov 26. Nat Med. 2018. PMID: 30478423 Clinical Trial.
CenTauR: Toward a universal scale and masks for standardizing tau imaging studies.
Villemagne VL, Leuzy A, Bohorquez SS, Bullich S, Shimada H, Rowe CC, Bourgeat P, Lopresti B, Huang K, Krishnadas N, Fripp J, Takado Y, Gogola A, Minhas D, Weimer R, Higuchi M, Stephens A, Hansson O, Doré V; Alzheimer's Disease Neuroimaging Initiative and the AIBL research group. Villemagne VL, et al. Among authors: bohorquez ss. Alzheimers Dement (Amst). 2023 Jul 7;15(3):e12454. doi: 10.1002/dad2.12454. eCollection 2023 Jul-Sep. Alzheimers Dement (Amst). 2023. PMID: 37424964 Free PMC article.
Preclinical development of ZED8, an 89Zr immuno-PET reagent for monitoring tumor CD8 status in patients undergoing cancer immunotherapy.
Ogasawara A, Kiefer JR, Gill H, Chiang E, Sriraman S, Ferl GZ, Ziai J, Bohorquez SS, Guelman S, Wang X, Yang J, Phan MM, Nguyen V, Chung S, Yu C, Tinianow J, Waaijer SJH, De Crespigny A, Marik J, Boswell CA, Zabka T, Staflin K, Williams SP. Ogasawara A, et al. Among authors: bohorquez ss. Eur J Nucl Med Mol Imaging. 2023 Jan;50(2):287-301. doi: 10.1007/s00259-022-05968-6. Epub 2022 Oct 22. Eur J Nucl Med Mol Imaging. 2023. PMID: 36271158
Correction to: Preclinical development of ZED8, an 89Zr immuno‑PET reagent for monitoring tumor CD8 status in patients undergoing cancer immunotherapy.
Ogasawara A, Kiefer JR, Gill H, Chiang E, Sriraman S, Ferl GZ, Ziai J, Bohorquez SS, Guelman S, Wang X, Yang J, Phan MM, Nguyen V, Chung S, Yu C, Tinianow J, Waaijer SJH, De Crespigny A, Marik J, Boswell CA, Zabka T, Staflin K, Williams SP. Ogasawara A, et al. Among authors: bohorquez ss. Eur J Nucl Med Mol Imaging. 2023 Jan;50(2):631. doi: 10.1007/s00259-022-06050-x. Eur J Nucl Med Mol Imaging. 2023. PMID: 36427067 No abstract available.
Safety and Pharmacokinetics/Pharmacodynamics of the First-in-Class Dual Action HER3/EGFR Antibody MEHD7945A in Locally Advanced or Metastatic Epithelial Tumors.
Juric D, Dienstmann R, Cervantes A, Hidalgo M, Messersmith W, Blumenschein GR Jr, Tabernero J, Roda D, Calles A, Jimeno A, Wang X, Bohórquez SS, Leddy C, Littman C, Kapp AV, Shames DS, Penuel E, Amler LC, Pirzkall A, Baselga J. Juric D, et al. Among authors: bohorquez ss. Clin Cancer Res. 2015 Jun 1;21(11):2462-70. doi: 10.1158/1078-0432.CCR-14-2412. Clin Cancer Res. 2015. PMID: 26034219 Free PMC article. Clinical Trial.